Career
Career orientation
Job market
Salary information and income survey
Academy
Mentoring
Education
Learners and trainees
Students and doctoral candidates
Teachers
University statictics
Scholarships
Community
Divisions
Local Sections
Regular's table
Chem_Connect
Equal opportunities, diversity
International activities and cooperations
Membership
Discover
Top topics
Nachrichten aus der Chemie
Brochures and scientific publications
Fascination with chemistry
Statements and position papers
Press releases
Events
Conferences
Local events
Academy
Awards
Prizes
Historical sites of chemistry
About
Board and other bodies
Office
Statutes
Angewandte Chemie and Chemistry Europe
Foundations
ChemRXiv
Florian Krieger
Moderation: Petra Schultheiß-Reimann
The use of artificial intelligence (AI) has become a key technological and scientific approach in preclinical drug research. By analysing high-dimensional biological and chemical data sets, AI methods make it possible to significantly accelerate and refine early development phases. Various AI-based approaches help to capture complex molecular relationships and provide data-driven support for experimental decision-making processes. The increasing integration and improvement of multimodal data sources as well as advances in AI approaches will further transform preclinical research.
Zoom link to the talk: https://us06web.zoom.us/j/85944698883?pwd=ekQRb3a3rqavoVkM6ZHR8VnVY946MQ.1There will be a five-minute start-up presentation before the talk. Dr Marcel Hövels from Sweethoven Biotech (sweethoven-biotech.com) will present the development of a sweet dietary fibre as a prebiotic and low-glycaemic sugar substitute.
